Results 1 to 10 of about 312,346 (337)

Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. [PDF]

PLoS ONE, 2014
Recent immune correlates analysis from the RV144 vaccine trial has renewed interest in the role of non-neutralizing antibodies in mediating protection from infection.
Anne-Sophie Dugast, Ying Chan, Michelle Hoffner, Anna Licht, Joseph Nkolola, Hualin Li, Hendrik Streeck, Todd J Suscovich, Musie Ghebremichael, Margaret E Ackerman, Dan H Barouch, Galit Alter   +11 more
doaj   +6 more sources

The Potent and Broadly Neutralizing Human Dengue Virus-Specific Monoclonal Antibody 1C19 Reveals a Unique Cross-Reactive Epitope on the bc Loop of Domain II of the Envelope Protein [PDF]

mBio, 2013
Following natural dengue virus (DENV) infection, humans produce some antibodies that recognize only the serotype of infection (type specific) and others that cross-react with all four serotypes (cross-reactive).
Scott A. Smith, A. Ruklanthi de Alwis, Nurgun Kose, Eva Harris, Kristie D. Ibarra, Kristen M. Kahle, Jennifer M. Pfaff, Xiaoxiao Xiang, Benjamin J. Doranz, Aravinda M. de Silva, S. Kyle Austin, Soila Sukupolvi-Petty, Michael S. Diamond, James E. Crowe   +13 more
doaj   +4 more sources

Antibody Response to SARS-CoV-2 among COVID-19 Confirmed Cases and Correlates with Neutralizing Assay in a Subgroup of Patients in Delhi National Capital Region, India

Vaccines, 2022
Background: The plaque reduction neutralization test (PRNT) is the gold standard to detect the neutralizing capacity of serum antibodies. Neutralizing antibodies confer protection against further infection.
Puneet Misra, Shashi Kant, Randeep Guleria, Sanjay K. Rai, Abhishek Jaiswal, Suprakash Mandal, Guruprasad R. Medigeshi, Mohammad Ahmad, Anisur Rahman, Meenu Sangral, Kapil Yadav, Mohan Bairwa, Partha Haldar, Parveen Kumar   +13 more
doaj   +1 more source

A sensitive and reproducible cell-based assay via secNanoLuc to detect neutralizing antibody against adeno-associated virus vector capsid

Molecular Therapy: Methods & Clinical Development, 2021
Most gene therapy clinical trials that systemically administered adeno-associated virus (AAV) vector enrolled only patients without anti-AAV-neutralizing antibodies.
Nemekhbayar Baatartsogt, Yuji Kashiwakura, Morisada Hayakawa, Nobuhiko Kamoshita, Takafumi Hiramoto, Hiroaki Mizukami, Tsukasa Ohmori   +6 more
doaj   +1 more source

A new strategy: identification of specific antibodies for neutralizing epitope on SARS-CoV-2 S protein by LC-MS/MS combined with immune repertoire

Molecular Biomedicine, 2022
Although the SARS-CoV-2 vaccine has been widely used worldwide, not all individuals can produce neutralization antibodies, so it is still urgent to find and prepare neutralization antibodies for COVID-19 prevention or treatment. In this study, we created
Meng Yu, Zhu Zhu, Yanqun Wang, Pingzhang Wang, Xiaodong Jia, Jie Wang, Lei Liu, Wanbing Liu, Yaqiong Zheng, Guomei Kou, Weiyan Xu, Jing Huang, Fengmin Lu, Xiajuan Zou, Shangen Zheng, Yinying Lu, Jincun Zhao, Hui Dai, Xiaoyan Qiu   +18 more
doaj   +1 more source

Dissecting the human serum antibody response to secondary dengue virus infections. [PDF]

PLoS Neglected Tropical Diseases, 2017
Dengue viruses (DENVs) are mosquito-borne flaviviruses and the causative agents of dengue fever and dengue hemorrhagic fever. As there are four serotypes of DENV (DENV1-4), people can be infected multiple times, each time with a new serotype.
Bhumi Patel, Patti Longo, Michael J Miley, Magelda Montoya, Eva Harris, Aravinda M de Silva   +5 more
doaj   +1 more source

Higher levels of neutralizing antibodies against KSHV in KS patients compared to asymptomatic individuals from Zambia. [PDF]

PLoS ONE, 2013
Kaposi sarcoma-associated herpesvirus (KSHV) is the etiologic agent for Kaposi Sarcoma (KS), the most common cancer diagnosed in HIV- infected patients.
Pankaj Kumar, Nithal Y Kuwa, Veenu Minhas, Clemence Marimo, Danielle M Shea, Chipepo Kankasa, Charles Wood   +6 more
doaj   +1 more source

Outliers Matter—Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies

Microorganisms, 2022
Vaccination against the SARS-CoV-2 virus or infection with SARS-CoV-2 will lead to the development of IgG antibodies against the S1 protein of the SARS-CoV-2 virus.
Berthold Hocher, Anne Schönbrunn, Xin Chen, Bernhard K. Krämer, Volker von Baehr   +4 more
doaj   +1 more source

HIV-1 Env Does Not Enable the Development of Protective Broadly Neutralizing Antibodies in an Experimental Autoimmune Encephalomyelitis Mouse Model

Frontiers in Immunology, 2021
Recent studies showed that immunological tolerance may restrict the development of Env-specific autoreactive broadly neutralizing antibodies. This evidence is consistent with the finding that Env immunization of a systemic lupus erythematosus (SLE ...
Gabriel Siracusano, Annamaria Finardi, Claudia Pastori, Vittorio Martinelli, Roberto Furlan, Lucia Lopalco   +5 more
doaj   +1 more source

Research progress on neutralizing epitopes and antibodies for the Rabies virus

Infectious Medicine, 2022
Rabies is a zoonotic infectious disease with a high fatality rate. It is caused by a virus in the genus Lyssavirus and is a global public health threat.
Chenjuan Shi, Peilu Sun, Pan Yang, Lele Liu, Li Tian, Wenkai Liu, Min Wang, Xuexing Zheng, Wenwen Zheng   +8 more
doaj   +1 more source